These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 33851281

  • 1. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
    Sarah B, Giovanna B, Emanuela K, Nadi N, Josè V, Alberto P.
    J Neurol; 2022 Feb; 269(2):733-741. PubMed ID: 33851281
    [Abstract] [Full Text] [Related]

  • 2. Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease.
    Winkler M, von Landenberg C, Kuchenbecker K, Reimann J, Kornblum C.
    Neuromuscul Disord; 2022 Mar; 32(3):195-205. PubMed ID: 35120758
    [Abstract] [Full Text] [Related]

  • 3. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.
    Harlaar L, Hogrel JY, Perniconi B, Kruijshaar ME, Rizopoulos D, Taouagh N, Canal A, Brusse E, van Doorn PA, van der Ploeg AT, Laforêt P, van der Beek NAME.
    Neurology; 2019 Nov 05; 93(19):e1756-e1767. PubMed ID: 31619483
    [Abstract] [Full Text] [Related]

  • 4. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
    Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, Karamouzian M, Toscano A.
    J Neurol; 2017 Apr 05; 264(4):621-630. PubMed ID: 27372449
    [Abstract] [Full Text] [Related]

  • 5. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study.
    Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der Meijden JC, Rizopoulos D, Brusse E, van Doorn PA, van der Ploeg AT, van der Beek NAME.
    Neurology; 2017 Dec 05; 89(23):2365-2373. PubMed ID: 29117951
    [Abstract] [Full Text] [Related]

  • 6. Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.
    Filosto M, Cotti Piccinelli S, Ravaglia S, Servidei S, Moggio M, Musumeci O, Donati MA, Pegoraro E, Di Muzio A, Maggi L, Tonin P, Marrosu G, Sancricca C, Lerario A, Sacchini M, Semplicini C, Bozzoni V, Telese R, Bonanno S, Piras R, Maioli MA, Ricci G, Vercelli L, Galvagni A, Gallo Cassarino S, Caria F, Mongini T, Siciliano G, Padovani A, Toscano A.
    Adv Ther; 2019 May 05; 36(5):1177-1189. PubMed ID: 30879255
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review.
    Ditters IAM, van Kooten HA, van der Beek NAME, van der Ploeg AT, Huidekoper HH, van den Hout JMP.
    Biomolecules; 2023 Sep 19; 13(9):. PubMed ID: 37759814
    [Abstract] [Full Text] [Related]

  • 9. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
    Stockton DW, Kishnani P, van der Ploeg A, Llerena J, Boentert M, Roberts M, Byrne BJ, Araujo R, Maruti SS, Thibault N, Verhulst K, Berger KI.
    J Neurol; 2020 Oct 19; 267(10):3038-3053. PubMed ID: 32524257
    [Abstract] [Full Text] [Related]

  • 10. The impact of interrupting enzyme replacement therapy in late-onset Pompe disease.
    Wenninger S, Gutschmidt K, Wirner C, Einvag K, Montagnese F, Schoser B.
    J Neurol; 2021 Aug 19; 268(8):2943-2950. PubMed ID: 33625582
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry.
    Scheidegger O, Leupold D, Sauter R, Findling O, Rösler KM, Hundsberger T.
    J Neurol; 2018 Dec 19; 265(12):2783-2788. PubMed ID: 30232608
    [Abstract] [Full Text] [Related]

  • 13. Effect of long term enzyme replacement therapy in late onset Pompe disease: A single-centre experience.
    Papadimas GK, Anagnostopoulos C, Xirou S, Michelakakis H, Terzis G, Mavridou I, Kararizou E, Papadopoulos C.
    Neuromuscul Disord; 2021 Feb 19; 31(2):91-100. PubMed ID: 33451932
    [Abstract] [Full Text] [Related]

  • 14. Enzymatic replacement therapy in patients with late-onset Pompe disease - 6-Year follow up.
    Witkowski G, Konopko M, Rola R, Ługowska A, Ryglewicz D, Sienkiewicz-Jarosz H.
    Neurol Neurochir Pol; 2018 Aug 19; 52(4):465-469. PubMed ID: 29803406
    [Abstract] [Full Text] [Related]

  • 15. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
    Byrne BJ, Geberhiwot T, Barshop BA, Barohn R, Hughes D, Bratkovic D, Desnuelle C, Laforet P, Mengel E, Roberts M, Haroldsen P, Reilley K, Jayaram K, Yang K, Walsh L, POM-001/002 Investigators.
    Orphanet J Rare Dis; 2017 Aug 24; 12(1):144. PubMed ID: 28838325
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
    Semplicini C, De Antonio M, Taouagh N, Béhin A, Bouhour F, Echaniz-Laguna A, Magot A, Nadaj-Pakleza A, Orlikowski D, Sacconi S, Salort-Campana E, Solé G, Tard C, Zagnoli F, Hogrel JY, Hamroun D, Laforêt P, French Pompe Study Group.
    J Inherit Metab Dis; 2020 Nov 24; 43(6):1219-1231. PubMed ID: 32515844
    [Abstract] [Full Text] [Related]

  • 18. Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease.
    van Kooten HA, Ditters IAM, Hoogeveen-Westerveld M, Jacobs EH, van den Hout JMP, van Doorn PA, Pijnappel WWMP, van der Ploeg AT, van der Beek NAME.
    Orphanet J Rare Dis; 2022 Feb 02; 17(1):31. PubMed ID: 35109913
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy.
    van der Meijden JC, Kruijshaar ME, Harlaar L, Rizopoulos D, van der Beek NAME, van der Ploeg AT.
    J Inherit Metab Dis; 2018 Nov 02; 41(6):1205-1214. PubMed ID: 29556838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.